Health Trials

Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

1

Review clinical trials related to Resectable Gastric/Gastroesophageal Junction Adenocarcinoma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

This is a Randomized, Double-Blind, Phase II/III Clinical Study of the Efficacy and Safety of Sintilimab Combined with Chemotherapy With or Without Ipilimumab N01 in Perioperative Treatment of Resectable Gastric/Gastroesophageal Junction Adenocarcinoma.

Participants needed: 720
Trial details
Phase: Phase 2, Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.Updated: Jun 11, 2026Locations: 1
Eligibility criteria

Signed written Informed Consent Form (ICF) and ability to comply with protocol-s... [+6]

Histologically or cytologically confirmed other pathologic types (e.g., squamous... [+6]

Read more